LIEPHARM
Timeline
20 events since 2015Board
Capital
Filings
Financial
End
Address
201620182020202220242026
2024
Annual accounts 2023 filed PDFfull format · 6 days before the deadline
Merger: absorbed by PHARMACIE BUSTINDissolution of the company · Dissolved without liquidation · holds 100% of the shares · General meeting of 28-06-20244 points ▸
- General meeting, 28-06-2024
- holds 100% of the shares, mentioned twice in the deed
- Accounting effect, 01-01-2024
- Director discharge, organe d'administration de la société LIEPHARM
- The deed holds 11 more points.
- holds all the shares, mentioned 10 times in the deed
- Accounting effect, 01-01-2024
- The deed holds 3 more points.
Registered office moved to VerviersNew registered office: rue de Mangombroux 161, 4800 VERVIERS · Resignations: (director) and (director) · Appointments: , (statutory auditor) and (daily management delegate) · General meeting of 10-01-202411 points ▸
- General meeting, 10-01-2024
- Director resignation,
- Director resignation,
- Director discharge,
- Director discharge,
- Director appointment,
- Permanent representative,
- Auditor appointment, (statutory auditor)
- Board meeting, 10-01-2024
- Registered-office move, rue de Mangombroux 161, 4800 VERVIERS
- Director appointment, (daily management delegate)
- The deed holds 2 more points.
Changes of role: (director) and (director)Director discharge: · Director discharge: · General meeting of 29-11-20239 points ▸
- Director resignation, (manager)
- Director appointment, (director (not named in the articles))
- Director resignation, (manager)
- Director appointment, (director (not named in the articles))
- Director discharge,
- Director discharge,
- Registered office clause, Chaussée de Liège 426, 4460 Grâce-Hollogne
- General meeting, 29-11-2023
- 210 shares
- The deed holds 5 more points.
2023
Annual accounts 2022 filed PDFfull format · 19 days before the deadline
2022
Equity above €200,000 equity €235,982 ▲27.2% After 6 profitable years in a row, equity reaches €235,982.
Annual accounts 2021 filed PDFfull format · 11 days before the deadline
2021
Annual accounts 2020 filed PDFfull format · 44 days before the deadline
2020
Highest result from 2015 to 2023 net €72,570 ▲163% The operating result of €98,199 and the net result of €72,570 are both a record.
Equity above €150,000 equity €174,087 ▲71.5% After 4 profitable years in a row, equity reaches €174,087.
Annual accounts 2019 filed PDFfull format · 20 days late
2019
Equity above €100,000 equity €101,517 ▲37.4% After 3 profitable years in a row, equity reaches €101,517.
Annual accounts 2018 filed PDFfull format · 1 day before the deadline
2018
Annual accounts 2017 filed PDFfull format · 20 days late
2017
Back to profit net €65,546 The net result is €65,546, after 2 loss-making years.
Annual accounts 2016 filed PDFfull format · 30 days late
2016
Weakest financial year net -€43,824 The net result drops to -€43,824, the lowest from 2015 to 2023.
Annual accounts 2015 filed PDFfull format · 21 days late
2015
Incorporation PDF5 publications in the Belgian Official Gazette, the last on 23-07-2024
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
The registered office was moved to Verviers in 2024.1 The board currently has 2 members.1 In 2024 LIEPHARM was absorbed by merger into PHARMACIE BUSTIN.2